SuPine Therapeutics has developed first-in-class therapeutics for spinal cord injury, which is an incurable condition. SGS101 is an implantable natural polymer-based hydrogel which can be applied in golden-time to protect injured tissue and provide optimal environments for neuroregeneration.

SuPine Therapeutics has developed direct conversion technology to generate target cells from somatic cells(e.g. skin cells). Our technology enables the generation of various cell types; iOPCs, iMNs, iHepSCs, iVPCs and iMoPs that are feasible for cell therapy to treat degenerative diseases.

SuPine Therapeutics has developed the technology to generate tissue-mimic assembloid by combining ECM-based biomaterials and patient-specific stem cells that are derived by direct conversion.

The multi-cell assembloids can be utilized as tissue therapy to replace the injured tissue or lost tissue.

The multi-cell assembloids can be utilized as disease models to screen toxicity of the newly developing drugs or to analyze the efficacy of the drugs.